Mary Kay Continues Its Commitment to Skin Science
13.1.2022 16:03:00 EET | Business Wire | Press release
Mary Kay Inc., one of the world’s innovative skincare companies, participated at two renowned European conferences in late 2021. At the 19th Aesthetic & Anti-Aging Medicine World Congress, Mary Kay Inc. submitted a scientific poster on the usage and tolerability of a highly concentrated retinol formula in Asian skin. Mary Kay Inc. also partnered with the European Society’s Dermatological Research (ESDR) in sponsoring Future Leaders in Dermatology Symposium at their 50th Annual conference. At this conference, Mary Kay Inc. shared the results of a recent clinical study that demonstrated the capability of a cosmetic formulation to alleviate symptoms associated with sensitive skin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005071/en/
Dr. Lucy Gildea, Mary Kay Chief Innovation Officer, Product and Science (Photo: Mary Kay Inc.)
The 19th Aesthetic & Anti-Aging Medicine World Congress took place from September 16-18, 2021, in Monte Carlo and was held under the High Patronage of H.S.H. Prince Albert II of Monaco. Attendees of this conference extended to several professions including dermatologists, plastic and cosmetic surgeons, anti-aging doctors, and aesthetic and general practitioners. Over 8,300 participants from 130 countries joined the conference, both in-person and virtually. The digital platform offered an immersive virtual experience that complemented the physical show allowing attendees to join the digital exhibition and watch workshops regardless of the distance or travel restrictions.
Mary Kay scientists were proud to share their latest research on retinol use and tolerability at this conference. By using a gradual retinization protocol on Asian individuals, there was an improvement in their overall skin appearance as well as a reduction in post-inflammatory hyperpigmentation - a common concern when using retinol, especially in skin of color.
“Retinol is a gold-standard skincare ingredient with many proven benefits, but the experience and tolerability of a retinol product are not the same for every person. For individuals who are concerned about potential irritation or hyperpigmentation, the results of this study offer potential solutions. I am very excited to share this research with the scientific community worldwide at AMWC’s 19th World Congress to share our innovative research with professionals in skin science and aging,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.
“AMWC 2021 featured a multi-faceted aesthetic and anti-aging medicine program aimed at promoting high-level continued education and we were happy to have Mary Kay participate this year. We hope that we have succeeded in helping to inspire the exchange of new ideas and the sharing of ‘know-how’ in this field on a global level”, said Catherine Decuyper, EuroMediCom Founder and President. “I am grateful to our team, our global partners, the attendees, and the scientific community at large for their contributions and for the opportunity to serve them and their aesthetic and anti-aging medicine needs.”
Following the success of AMWC 2021, EuroMediCom will host AMWC 2022 from March 31 to April 2, 2022, in a hybrid format again in order to allow delegates from across the world to join them for the 20th edition of their world-leading aesthetic and anti-aging medicine congress. Registrants can choose to attend in person or watch live-streamed sessions from anywhere in the world.
The annual European Society’s Dermatological Research (ESDR) Conference is held in Europe each year every September. In 2021, due to travel restrictions and COVID-19 precautions, the annual meeting took place entirely virtually from September 22-15, 2021. ESDR supports investigative dermatology with the goal of improving the health of patients who are suffering from various skin and infectious diseases and immune disorders. In addition to presenting research, Mary Kay was also able to sponsor a Future Leaders in Dermatology symposium that kicked off the conference.
Associate Principal Scientist Geetha Kalahasti at Mary Kay Inc. shared the results of a recent clinical study that evaluated the effects of a new formulation that contained a blend of lipids identical to the skin's natural ratio, a nociceptor (TRPV-1) antagonist, and a botanical extract that reduces the expression of proinflammatory cytokines.
“At Mary Kay, we are committed to understanding skin biology and designing new products that address skin needs. One ongoing area of focus has been the relationship between sensitive skin and skin barrier function,” said Kalahasti. “Each of these materials targeted a specific biological pathway that contributes to skin redness. The findings revealed that this multi-faceted approach helps strengthen the compromised skin barrier and alleviate discomfort associated with sensitive skin.”
“On behalf of the ESDR board, we would like to thank Mary Kay for the support of the ESDR and the generous contribution to ESDR activities. One of the most important activities of our Society is to promote the presentation of new research data and ideas, and we are delighted to have Mary Kay be a part of this event,” said Leopold Eckhart, Chair, Scientific Program Committee of ESDR.
This particular symposium helps connect young researchers with renowned scientists in dermatology and encourages such collaborations – a focus that is very important to Mary Kay Inc.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
ABOUT EUROMEDICOM
EuroMediCom, created in 1999 and part of Informa Exhibitions since 2010, is dedicated to promoting Life Sciences and knowledge through educational Trainings, Conferences & Exhibitions. The main event, AMWC was created in 2003 and has since become the largest and leading medical aesthetic congress in the world. AMWC was developed with the strong belief that external aesthetic treatments and internal aging prevention could be comprehensively addressed by integrating two aspects: aesthetics strategy through dermatology and surgery procedures for external appearance and anti-aging medicine for prevention of aging and enhancement of aesthetic treatments. For more information about AMWC, click here: https://www.euromedicom.com/en/home.html
ABOUT THE EUROPEAN SOCIETY DERMATOLOGICAL RESEARCH (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases, and immune-mediated and inflammatory disorders. The ESDR facilitates exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005071/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release
India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom